Edwin J Vazquez-Cintron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4500969/publications.pdf

Version: 2024-02-01

		1163117	1372567
11	181	8	10
papers	citations	h-index	g-index
15	15	15	261
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Tumor-Induced Disruption of Proximal TCR-Mediated Signal Transduction in Tumor-Infiltrating CD8+ Lymphocytes Inactivates Antitumor Effector Phase. Journal of Immunology, 2010, 185, 7133-7140.	0.8	41
2	Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. Cell Reports, 2020, 30, 2526-2539.e6.	6.4	24
3	Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Science Translational Medicine, $2021,13,.$	12.4	22
4	Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery. Scientific Reports, 2017, 7, 42923.	3.3	20
5	Atoxic Derivative of Botulinum Neurotoxin A as a Prototype Molecular Vehicle for Targeted Delivery to the Neuronal Cytoplasm. PLoS ONE, 2014, 9, e85517.	2.5	19
6	Protocadherin-18 Is a Novel Differentiation Marker and an Inhibitory Signaling Receptor for CD8+ Effector Memory T Cells. PLoS ONE, 2012, 7, e36101.	2.5	17
7	Symptomatic treatment of botulism with a clinically approved small molecule. JCI Insight, 2020, 5, .	5.0	14
8	Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function. Toxins, 2020, 12, 611.	3.4	11
9	Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety. Scientific Reports, 2016, 6, 30429.	3.3	9
10	Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine. Molecular Medicine, 2022, 28, .	4.4	3
11	Design options for mRNA-encoded BoNT Antitoxins employing camelid single-domain antibody (VHH) components. Toxicon, 2018, 156, S104-S105.	1.6	0